Urologix (ULGX) 10-Q 14 May 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Entity Registrant Name	UROLOGIX INC
Entity Central Index Key	882873
Current Fiscal Year End Date	-24
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,817,726

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash	$492	$718	[1]
Restricted cash	40
Accounts receivable, net of allowance of $46 and $76, respectively	1,392	1,502	[1]
Inventories	1,319	1,397	[1]
Prepaids and other current assets	160	63	[1]
Total current assets	3,403	3,680	[1]
Property and equipment:
Property and equipment	12,144	12,162	[1]
Less accumulated depreciation	-11,853	-11,691	[1]
Property and equipment, net	291	471	[1]
Other intangible assets, net	1,230	1,370	[1]
Long-term inventories	94	141	[1]
Other assets	5	5	[1]
Total assets	5,023	5,667	[1]
Current liabilities:
Accounts payable	708	892	[1]
Accrued compensation	371	487	[1]
Short-term deferred acquisition payment	2,044	1,339	[1]
Current portion of long-term debt (Note 12)	1,795	747	[1]
Interest payable	634	322	[1]
Other accrued expenses	577	505	[1]
Total current liabilities	6,129	4,292	[1]
Long-term deferred acquisition payment	3,412	3,730	[1]
Long-term debt (Note 12)	3,537	4,586	[1]
Other accrued expenses	8	36	[1]
Total liabilities	13,086	12,644	[1]
Commitments and Contingencies (Note 13)			[1]
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 30,000 shares authorized; 21,818 and 21,291 shares issued; and 21,282 and 20,945 shares outstanding	213	209	[1]
Additional paid-in capital	119,493	119,440	[1]
Accumulated deficit	-127,769	-126,626	[1]
Total shareholders' deficit	-8,063	-6,977	[1]
Total liabilities and shareholders' deficit	$5,023	$5,667	[1]
[1]	The Balance Sheet at June 30, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified
Condensed Balance Sheets [Abstract]
Accounts receivable, allowances (in dollars)	$46	$76
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	30,000,000	30,000,000
Common stock, shares issued (in shares)	21,818,000	21,291,000
Common stock, shares outstanding (in shares)	21,282,000	20,945,000

Condensed_Statements_Of_Operat

Condensed Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Condensed Statements Of Operations [Abstract]
SALES	$2,796	$3,356	$8,896	$10,941
COST OF GOODS SOLD	1,485	2,507	4,659	6,431
Gross profit	1,311	849	4,237	4,510
COSTS AND EXPENSES
Sales and marketing	657	1,313	2,196	4,839
General and administrative	449	527	1,404	1,773
Research and development	298	408	969	1,281
Change in value of acquisition consideration		-12		-105
Medical device tax	44	52	140	172
Amortization of identifiable intangible assets	16	28	56	72
Total costs and expenses	1,464	2,316	4,765	8,032
OPERATING LOSS	-153	-1,467	-528	-3,522
INTEREST EXPENSE	-190	-178	-594	-516
FOREIGN CURRENCY EXCHANGE (GAIN)/LOSS	-6	-1	-12	1
LOSS BEFORE INCOME TAXES	-349	-1,646	-1,134	-4,037
INCOME TAX EXPENSE		18	9	46
NET LOSS	($349)	($1,664)	($1,143)	($4,083)
NET LOSS PER COMMON SHARE - BASIC	($0.02)	($0.08)	($0.05)	($0.19)
NET LOSS PER COMMON SHARE - DILUTED	($0.02)	($0.08)	($0.05)	($0.19)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	21,838	21,326	21,701	21,195
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	21,838	21,326	21,701	21,195

Condensed_Statements_Of_Cash_F

Condensed Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
OPERATING ACTIVITIES
Net loss	($1,143)		($4,083)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	361		447
Employee stock-based compensation expense	53		169
Provision for bad debts	20		-7
Prostiva inventory reserve			739
Loss on disposal of assets	2		3
Accretion expense on deferred acquisition payments	387		334
Net adjustment to acquisition consideration			-105
Deferred income taxes			27
Change in operating assets and liabilities:
Accounts receivable	90		342
Inventories	99		336
Prepaids and other assets	-97		-86
Accounts payable	-184		387
Other accrued expenses	-72		-187
Interest payable	312		245
Net cash used for operating activities	-172		-1,439
INVESTING ACTIVITIES
Purchases of property and equipment	-8		-28
Purchases of intellectual property	-15		-7
Proceeds from sale of property and equipment	9
Cash restricted for collateral	-40
Net cash used for investing activities	-54		-35
NET DECREASE IN CASH	-226		-1,474
CASH
Beginning of period	718	[1]	2,290
End of period	492		816
Supplemental cash-flow information
Income taxes paid during the period	9		27
Net carrying amount of inventory transferred to property and equipment	$25		$46
[1]	The Balance Sheet at June 30, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

Basis_Of_Presentation

Basis Of Presentation	9 Months Ended
	Mar. 31, 2015
Basis Of Presentation [Abstract]
Basis Of Presentation	1.               Basis of Presentation
	The accompanying unaudited condensed financial statements of Urologix, Inc. (the “Company,” “Urologix,” “we”) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. The balance sheet as of March 31, 2015 and the statements of operations and cash flows for the three and nine-months ended March 31, 2015 and 2014 are unaudited but include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of the financial position at such date, and the operating results and cash flows for those periods. Certain information normally included in financial statements and related footnotes prepared in accordance with generally accepted accounting principles has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The accompanying financial statements should be read in conjunction with the financial statements and notes included in the Urologix Annual Report on Form 10-K for the year ended June 30, 2014, which includes a going concern qualification.
	Results for any interim period shown in this report are not necessarily indicative of results to be expected for any other interim period or for the entire year.

Use_Of_Estimates

Use Of Estimates	9 Months Ended
	Mar. 31, 2015
Use Of Estimates [Abstract]
Use Of Estimates	2.               Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and assumptions are based on management’s best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors that management believes to be reasonable under the circumstances, including the current economic environment. The Company adjusts such estimates and assumptions when facts and circumstances dictate. These include, among others, the continued difficult economic conditions, tight credit markets, Medicare reimbursement rate uncertainty, and a decline in consumer spending and confidence, all of which have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual amounts could differ significantly from those estimated at the time the financial statements are prepared. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.

Liquidity

Liquidity	9 Months Ended
	Mar. 31, 2015
Liquidity [Abstract]
Liquidity	3.                Liquidity
	As of March 31, 2015, the Company’s cash balance was $532,000, including $40,000 of restricted cash. The Company incurred net losses of $1.1 million for the nine-month period ended March 31, 2015 and $7.6 million and $4.3 million in the fiscal years ended June 30, 2014 and 2013, respectively. In addition, the Company has accumulated aggregate net losses from the inception of business through March 31, 2015 of $127.8 million.
	On June 28, 2013, the Company entered into a restructuring agreement with Medtronic related to the $7.5 million it then owed to Medtronic under the September 2011 Prostiva license transaction documents.  As part of this agreement, we paid Medtronic $2.0 million in satisfaction of certain amounts owed under the transaction documents and entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed.  Interest on the Note accrues at a rate of 6 percent, compounded annually, and is payable in five equal installments of principal and accrued interest, on March 31st of each year beginning on March 31, 2015. The obligations on the Note are secured by substantially all of the Company’s assets (excluding intellectual property).  The Company’s cash balance at March 31, 2015 was inadequate to repay Medtronic the required $1.3 million principal and interest payment on the Note nor was it adequate subsequent to March 31, 2015 to make the payment. Because the Company had not made the required payment on the Note within 10 business days of the March 31, 2015 due date, an event of default on the Note occurred in April 2015.  Because of the event of default under the Note, Medtronic has the right to declare all amounts under the Note immediately due and payable and to exercise any of its other rights and remedies as a secured party. See Note 15 – Subsequent Event.
	Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year.  The Company has not paid, as of March 31, 2015 or subsequently, two royalty payments, each in the amount of $650,000, that were due on October 4, 2013 and October 6, 2014.  Accordingly, royalty payments totaling $1.3 million are included in the short-term deferred acquisition payment liability as of March 31, 2015.  The Company has also not paid, as of March 31, 2015 or subsequently,  the annual $65,000 license maintenance fees due on each of September 6, 2013 and September 6, 2014.  The total license maintenance fee of $130,000 is included in other accrued expenses as of March 31, 2015.  Including interest, total amounts due and unpaid to Medtronic as of March 31, 2015 are approximately $2.8 million.  Because the Company had not made the required $1.3 million payment on the Note within 10 business days of the March 31, 2015 due date, an event of default on the Note occurred on April 14, 2015.  Because of the event of default under the Note, Medtronic has the right to declare all amounts under the Note immediately due and payable (an additional $4.6 million as of April 14, 2015) and to exercise any of its other rights and remedies as a secured party under applicable law and the security agreement.
	The Company’s cash balance at March 31, 2015 was inadequate to repay amounts owed to Medtronic or to cure any default under the license agreement or the Note.  Because the Company’s cash is not sufficient to sustain day-to-day operations for the next 12 months, the Company’s ability to continue as a going concern is dependent upon our ability to address our outstanding indebtedness to Medtronic.  The Company believes that this debt is most likely to be addressed through one or more strategic alternatives.
	Strategic alternatives include sale of the Company or its assets, merging with another company, renegotiating its obligations with Medtronic, raising capital by incurring additional debt or raising capital through an offering of its debt or equity securities or both.  Because all of the Company’s assets (exclusive of intellectual property) are subject to a lien in favor of Medtronic and because of our limited cash flow available for debt service, the Company does not believe raising capital through incurring additional debt is a viable alternative at this time .  Further, the Company does not believe raising capital through the sale of equity is a viable alternative at this time.  No assurance can be given that the Company will successfully realize any strategic alternative or that the strategic alternative will be executed within any particular timeframe or on terms and conditions acceptable to Urologix, its creditors or its shareholders. The Company’s failure to address its indebtedness to Medtronic to Medtronic’s satisfaction may result in acceleration of all obligations on the Note, seizure by Medtronic of the assets that secure the Company’s indebtedness, loss of control of the Company’s business, bankruptcy or cessation of the business.
	The Company has also implemented operational initiatives designed to enhance the value of the Company and the viability of strategic alternatives and to improve the Company’s cash and liquidity position while these alternatives are pursued.  As part of these operational initiatives, the Company implemented restructuring plans in January 2014 and again in April 2014 to reduce our cash utilization. The operating expense savings from these restructurings total $4.4 million for the twelve-month period ended March 31, 2015 compared with the same period of the prior year.  Additional operational initiatives focus on generating additional revenues from sales of both Cooled ThermoTherapy and Prostiva products, negotiating payment terms with our vendors, and managing expenses—including those associated with public reporting.  There can be no assurance that the Company’s operational initiatives will be successful in supporting the Company’s efforts to pursue strategic alternatives or improving its cash and liquidity position in the short-term sufficient to meet its obligations.
	The financial statements as of and for the nine-months ended March 31, 2015 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	4.Fair Value Measurements
	The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and non-recurring basis. Under this guidance, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy is broken down into three levels defined as follows:
		•	Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.
		•	Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.
		•	Level 3 - Inputs are unobservable for the asset or liability.
	As part of the consideration for the Prostiva acquisition, the estimated royalty payments between the minimum and maximum amounts are considered contingent consideration.  The contingent consideration was measured at fair value at the acquisition date and is remeasured to fair value at each reporting date until the contingency is resolved using Level 3 inputs.  The Level 3 inputs consist of the projected fiscal year of payments based on projected revenues and an estimated discount rate.  The fair value is determined by applying an appropriate discount rate that reflects the risk factors associated with the payment streams.  The changes in fair value that do not relate to the initial recognition of the liability as of the acquisition date are recognized in earnings.  The Company estimates the fair value of the future contingent consideration at approximately $1.1 million as of March 31, 2015.  There was no change in the fair value of contingent or non-contingent consideration for the nine-month period ended March 31, 2015, only increased accretion expense of approximately $110,000.  The following table provides a reconciliation of the beginning and ending balances of the contingent consideration liability:
		Nine months ended
	(in thousands)	31-Mar-15
	Beginning balance - contingent consideration	$	953
	Accretion expense		110
	Ending balance - contingent consideration		1,063
	Contractual consideration		4,393
	Total deferred acquisition liability	$	5,456

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Mar. 31, 2015
Stock-Based Compensation [Abstract]
Stock-Based Compensation	5.Stock-Based Compensation
	On November 16, 2012, our shareholders approved a new equity compensation plan, the Urologix, Inc. 2012 Stock Incentive Plan (the “2012 Plan”).  The 2012 Plan replaced our Amended and Restated 1991 Stock Option Plan (the “1991 Plan”) and provides stock incentive awards in the form of options (incentive and non-qualified), stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other awards in stock and/or cash.  As of March 31, 2015, we had reserved 2,372,309 shares of common stock under the 2012 Plan, which includes 772,309 expired and forfeited shares from the 1991 Plan, and 1,326,703 shares were available for future grants.    The number of shares available under the 2012 Plan will be increased by an amount equal to the number of shares subject to awards or options granted under the 1991 Plan which would have become available for additional awards under the 1991 Plan by reason of forfeiture, cancellation, expiration or termination of those awards.  Options expire 10 years from the date of grant and typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter.
	Amounts recognized in the financial statements for the three and nine-months ended March 31, 2015 and 2014 related to stock-based compensation were as follows (in thousands):
			Three months ended					Nine months ended
			March 31,					March 31,
			2015			2014		2015		2014
	Cost of goods sold		$	1		$	2	$	2	$	7
	Sales and marketing			6			12		15		40
	General and administrative			8			27		33		102
	Research and development			1			6		3		20
	Total stock-based compensation		$	16		$	47	$	53	$	169
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We use historical data to estimate expected volatility, the period of time that option grants are expected to be outstanding, as well as employee termination behavior. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. There were no stock options granted during the nine-month period ended March 31, 2015.  The following assumptions were used to estimate the fair value of options granted during the nine-months ended March 31, 2014 using the Black-Scholes option-pricing model:
	Volatility	83.66	%
	Risk-free interest rate	0.67	%
	Expected option life	3.1	years
	Stock dividend yield	-
	A summary of our option activity for the nine months ended March 31, 2015 is as follows:
		Number of Options		Weighted-avg. Exercise Price Per Option	Weighted-avg. Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at July 1, 2014	1,704,042	$	1.35		$	-
	Options granted	-		-
	Options forfeited	-31,044		0.52
	Options expired	-503,125		1.79
	Outstanding at March 31, 2015	1,169,873	$	1.18	5.14	$	-
	Exercisable at March 31, 2015	1,024,729	$	1.26	4.76	$	-
	There is no intrinsic value for options outstanding as our closing stock price was lower than all options outstanding and exercisable as of the dates above.
	A summary of restricted stock award activity for the nine-month period ended March 31, 2015 is as follows:
		Number of Restricted Stock Awards		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2014	346,302	$	0.28
	Awards granted	571,820		0.11
	Awards forfeited	-55,000		0.18
	Awards vested	-327,500		0.27
	Non-vested at March 31, 2015	535,622		0.11
	In addition, 10,000 shares of stock were granted during the nine-month period ended March 31, 2015 related to a performance stock award.
	As of March 31, 2015, total unrecognized compensation cost related to non-vested stock options and restricted stock awards granted under the Plan was $46,000 and $37,000, respectively. That cost is expected to be recognized over a weighted-average period of 1.6 years for non-vested stock options and 2.4 years for restricted stock awards.

Basic_And_Diluted_Loss_Per_Sha

Basic And Diluted Loss Per Share	9 Months Ended
	Mar. 31, 2015
Basic And Diluted Loss Per Share [Abstract]
Basic And Diluted Loss Per Share	6.Basic and Diluted Loss Per Share
	Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and participating securities outstanding during the periods presented. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and participating securities outstanding plus all dilutive potential common shares that result from stock options. The weighted average common shares outstanding (in thousands) for both basic and dilutive, were 21,838 and 21,326, for the three-months ended March 31, 2015 and 2014, respectively and 21,701 and 21,195, for the nine-months ended March 31, 2015 and 2014, respectively.
	The dilutive effect of stock options excludes approximately 1.18 million and 1.79 million awards for the three-months ended March 31, 2015 and 2014, respectively,  and 1.43 million and 1.81 million for the nine-months ended March 31, 2015 and 2014, respectively, for which the exercise price was higher than the average market price. In addition, there were no potentially dilutive stock options where the exercise price was lower than the average market price for the three and nine-month periods ended March 31, 2015 and 2014, respectively.

Restricted_Cash

Restricted Cash	9 Months Ended
	Mar. 31, 2015
Restricted Cash [Abstract]
Restricted Cash	7.Restricted Cash
	Restricted cash consists of a reserve account required on our corporate credit cards.  The cash becomes unrestricted upon cancellation of the credit cards.

Intangible_Assets

Intangible Assets	9 Months Ended
	Mar. 31, 2015
Intangible Assets [Abstract]
Intangible Assets	8.Intangible Assets
	Intangible assets as of March 31, 2015 and June 30, 2014 consisted of the following (in thousands):
			31-Mar-15								30-Jun-14
									Net								Net
			Carrying		Accumulated				Carrying		Carrying		Accumulated				Carrying
			Value		Amortization		Impairment		Value		Value		Amortization		Impairment		Value
	Prostiva Acquisition
	Patents and Technology	$	1,529	$	-542	$	-274	$	713	$	1,529	$	-443	$	-274	$	812
	Customer Base		531		-188		-95		248		531		-154		-95		282
	Trademarks		325		-64		-65		196		325		-53		-65		207
	EDAP Acquisition
	Customer Base		2,300		-2,300		-		-		2,300		-2,294		-		6
	Other		88		-15		-		73		74		-11		-		63
	Total intangible assets	$	4,773		-3,109	$	-434	$	1,230	$	4,759		-2,955	$	-434	$	1,370
	Amortization expense associated with intangible assets for the three and nine-months ended March 31, 2015 and 2014 was $49,000 and $61,000, respectively and $154,000 and $172,000, respectively. As a result of the delisting of our common stock from the NASDAQ exchange at the start of trading on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013.  Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired.  As a result, we recorded an impairment charge as of June 30, 2013 of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense. The fair value of patents and technology, customer base and trademark intangible assets was determined based on a discounted cash flow analysis of forecasted future operating results.
	All intangible assets are amortized using the straight-line method over their estimated remaining useful lives. Patents and technology related to the Prostiva acquisition are being amortized over 9 years with amortization expense recorded in cost of goods sold. Customer base and trademarks related to the Prostiva acquisition are being amortized over 9 years and 16 years, respectively. Other intangible assets related to patent costs are amortized upon issuance over their estimated useful lives.
	Future amortization expense related to the net carrying amount of intangible assets is estimated to be as follows (in thousands):
	Fiscal Years
	2015	$	50
	2016		199
	2017		199
	2018		198
	2019		196

Inventories

Inventories	9 Months Ended
	Mar. 31, 2015
Inventories [Abstract]
Inventories	9.Inventories
	Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis and consist of (in thousands):
		31-Mar-15		30-Jun-14
	Raw materials	$	641	$	685
	Work-in-process		157		127
	Finished goods		615		726
	Total inventories	$	1,413	$	1,538
	In the third quarter of fiscal year 2014, we took a non-cash write-down of our Prostiva capital equipment inventory of approximately $739,000, which included approximately $504,000 of finished goods inventory acquired in the Prostiva acquisition.  This inventory continues to be reserved for as of March 31, 2015.  Approximately $94,000 and $141,000 of the above finished goods balance as of March 31, 2015 and June 30, 2014, respectively, represents long-term inventories that the Company does not expect to sell within the next 12 months, however, they are also not considered excess or obsolete.

Income_Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Income Taxes	10.Income Taxes
	As of June 30, 2014, the liability for gross unrecognized tax benefits was $14,000. During the nine-months ended March 31, 2015, there were no significant changes to the total gross unrecognized tax benefits. It is expected that the amount of unrecognized tax benefits for positions which the Company has identified will not change significantly in the next twelve months.
	The Company files income tax returns in the United States (U.S.) federal jurisdiction as well as various state jurisdictions. The Company is subject to U.S. federal income tax examinations by tax authorities for fiscal years after 1999 due to unexpired net operating loss carryforwards originating in and subsequent to that fiscal year. The Company may also be subject to state income tax examinations whose regulations vary by jurisdiction.

Warranty

Warranty	9 Months Ended
	Mar. 31, 2015
Warranty [Abstract]
Warranty	11.Warranty
	Some of the Company’s products, including the Prostiva products, are covered by warranties against defects in material and workmanship for periods of up to 24 months. The Company records a liability for warranty claims during the period of the sale. The amount of the liability is based on the trend in the historical ratio of product failure rates, material usage and service delivery costs to sales, the historical length of time between the sale and resulting warranty claim, and other factors.
	Warranty provisions and claims for the nine-months ended March 31, 2015 and 2014 were as follows (in thousands):
		Nine Months Ended
		31-Mar-15		31-Mar-14
	Beginning Balance	$	56	$	58
	Warranty Provision		6		35
	Warranty Claims		-25		-30
	Ending Balance	$	37	$	63

Financing_Arrangements

Financing Arrangements	9 Months Ended
	Mar. 31, 2015
Financing Arrangements [Abstract]
Financing Arrangements	12.Financing Arrangements
	Promissory Note
	On June 28, 2013, the Company entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition.  Interest on the principal amount of the Note will accrue at the annual rate of 6%, compounded annually. The Note requires that the Company make five equal annual payments of principal and accrued interest on March 31 of each year beginning March 31, 2015. All amounts under the Note are due and payable on March 31, 2019 or earlier upon a Change of Control (as defined in the Note).  The Company may prepay the Note without penalty at any time. The Note is junior to a new lender that provides certain refinancing, but is senior in all respects (including right of payment) to all other existing or future indebtedness. The Note also specifies certain customary events of default that will entitle Medtronic, after any required notice, to declare the outstanding obligations immediately due and payable. The Note contains customary representations, warranties and covenants by the Company.
	Pursuant to the terms of a Security Agreement dated as of June 28, 2013 by and between Urologix and Medtronic, the Company’s obligations under the Note are secured by a security interest in all of the Company’s assets, specifically excluding intellectual property (but including accounts receivable and proceeds of intellectual property).
	The Company’s cash balance at March 31, 2015 was inadequate to repay Medtronic the required $1.3 million principal and interest payment on the Note nor was it adequate subsequent to March 31, 2015 to make the payment. Because the Company had not made the required $1.3 million payment on the Note within 10 business days of the March 31, 2015 due date, an event of default on the Note occurred in April 2015. Because of the event of default under the Note, Medtronic has the right to declare all amounts under the Note immediately due and payable and to exercise any of its other rights and remedies as a secured party. See also Note 15 – Subsequent Event.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13.Commitments and Contingencies
	Legal Proceedings
	The Company has been involved in various legal proceedings and other matters that arise in the normal course of its business, including product liability claims that are inherent in the testing, production, marketing and sale of medical devices. As of March 31, 2015, the Company was not involved in any legal proceedings or other matters that are expected to have a material effect on the financial position, liquidity or results of operations of the Company.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	9 Months Ended
	Mar. 31, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements	14.Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  The requirements are effective for annual reporting periods beginning after December 15, 2016.  Early adoption is not permitted.  We are evaluating the impact of the amended revenue recognition guidance on our financial statements.

Subsequent_Event

Subsequent Event	9 Months Ended
	Mar. 31, 2015
Subsequent Event [Abstract]
Subsequent Event	15.Subsequent Event
	The Company’s cash balance at March 31, 2015 was inadequate to repay Medtronic any principal or interest on the Note nor was it adequate subsequent to March 31, 2015 to make any principal or interest payment. Because the Company had not made the required $1.3 million payment on the Note within 10 business days of the March 31, 2015 due date, an event of default on the Note occurred on April 14, 2015.  Because of the event of default under the Note, Medtronic has the right to declare all amounts under the Note immediately due and payable (approximately $7.4 million as of April 14, 2015) and to exercise any of its other rights and remedies as a secured party under applicable law and the security agreement.
	By a letter dated April 9, 2015, Medtronic has notified the Company of its reservation of its legal rights under the Company’s agreements with Medtronic, including the Note, the security agreement and the license agreement, and Medtronic stated that it is entitled, at its option, at any time to (a) declare the entire outstanding principal and unpaid interest on the Note to be immediately due and payable, (b) terminate the Prostiva license agreement, (c) exercise its rights and remedies under the security agreement, including the right to possess, foreclose upon, sell or appoint a receiver in respect of the collateral as identified therein and (d) exercise any or all other rights and remedies available under any operative documents or under applicable law.  To date, Medtronic has not exercised its available rights and remedies, but there can be no assurance that it will not do so at any time.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2015
Fair Value Measurements [Abstract]
Reconciliation Of Contingent Consideration
		Nine months ended
	(in thousands)	31-Mar-15
	Beginning balance - contingent consideration	$	953
	Accretion expense		110
	Ending balance - contingent consideration		1,063
	Contractual consideration		4,393
	Total deferred acquisition liability	$	5,456

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2015
Stock-Based Compensation [Abstract]
Amounts Recognized In Financial Statements Related To Stock-Based Compensation
			Three months ended					Nine months ended
			March 31,					March 31,
			2015			2014		2015		2014
	Cost of goods sold		$	1		$	2	$	2	$	7
	Sales and marketing			6			12		15		40
	General and administrative			8			27		33		102
	Research and development			1			6		3		20
	Total stock-based compensation		$	16		$	47	$	53	$	169
Assumptions Used To Estimate Fair Value Of Options Granted
	Volatility	83.66	%
	Risk-free interest rate	0.67	%
	Expected option life	3.1	years
	Stock dividend yield	-
Summary Of Stock Option Activity
		Number of Options		Weighted-avg. Exercise Price Per Option	Weighted-avg. Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at July 1, 2014	1,704,042	$	1.35		$	-
	Options granted	-		-
	Options forfeited	-31,044		0.52
	Options expired	-503,125		1.79
	Outstanding at March 31, 2015	1,169,873	$	1.18	5.14	$	-
	Exercisable at March 31, 2015	1,024,729	$	1.26	4.76	$	-
Summary Of Non-Vested Restricted Stock Activitiy
		Number of Restricted Stock Awards		Weighted-avg. Grant-Date Fair Value
	Non-vested at June 30, 2014	346,302	$	0.28
	Awards granted	571,820		0.11
	Awards forfeited	-55,000		0.18
	Awards vested	-327,500		0.27
	Non-vested at March 31, 2015	535,622		0.11

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2015
Intangible Assets [Abstract]
Schedule Of Intangible Assets
			31-Mar-15								30-Jun-14
									Net								Net
			Carrying		Accumulated				Carrying		Carrying		Accumulated				Carrying
			Value		Amortization		Impairment		Value		Value		Amortization		Impairment		Value
	Prostiva Acquisition
	Patents and Technology	$	1,529	$	-542	$	-274	$	713	$	1,529	$	-443	$	-274	$	812
	Customer Base		531		-188		-95		248		531		-154		-95		282
	Trademarks		325		-64		-65		196		325		-53		-65		207
	EDAP Acquisition
	Customer Base		2,300		-2,300		-		-		2,300		-2,294		-		6
	Other		88		-15		-		73		74		-11		-		63
	Total intangible assets	$	4,773		-3,109	$	-434	$	1,230	$	4,759		-2,955	$	-434	$	1,370
Future Amortization Expense Related To Net Carrying Amount Of Intangible Assets
	Fiscal Years
	2015	$	50
	2016		199
	2017		199
	2018		198
	2019		196

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Mar. 31, 2015
Inventories [Abstract]
Schedule Of Inventories
		31-Mar-15		30-Jun-14
	Raw materials	$	641	$	685
	Work-in-process		157		127
	Finished goods		615		726
	Total inventories	$	1,413	$	1,538

Warranty_Tables

Warranty (Tables)	9 Months Ended
	Mar. 31, 2015
Warranty [Abstract]
Warranty Provisions And Claims
		Nine Months Ended
		31-Mar-15		31-Mar-14
	Beginning Balance	$	56	$	58
	Warranty Provision		6		35
	Warranty Claims		-25		-30
	Ending Balance	$	37	$	63

Liquidity_Details

Liquidity (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended			0 Months Ended
	Jun. 28, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014		Jun. 30, 2013	Apr. 14, 2015
Liquidity [Line Items]
Cash and restricted cash balance		$532,000		$532,000
Restricted cash		40,000		40,000
Net losses		-349,000	-1,664,000	-1,143,000	-4,083,000	-7,600,000		-4,300,000
Accumulated aggregate net losses from inception of business		-127,769,000		-127,769,000		-126,626,000	[1]
Amount of liabilities restructured	7,500,000
Cash paid related to Restructuring Agreement.	2,000,000
Promissory note payable		5,300,000		5,300,000
Promissory note, interest rate		6.00%		6.00%
Principal and interest payment due				1,300,000
Accrued royalties		1,300,000		1,300,000
License maintenance fee		130,000		130,000
Amount due and unpaid		2,800,000		2,800,000
Estimated expense reduction due to restructuring				4,400,000
Subsequent Event [Member]
Liquidity [Line Items]
Amount due and unpaid									7,400,000
Additional amount due and unpaid									4,600,000
Royalty Payment Due October 4, 2013 [Member]
Liquidity [Line Items]
Accrued royalties		650,000		650,000
Royalty Payment Due October 6, 2014 [Member]
Liquidity [Line Items]
Accrued royalties		650,000		650,000
License Maintenance Fee Due September 6, 2013 And September 6, 2014 [Member]
Liquidity [Line Items]
License maintenance fee		$65,000		$65,000
[1]	The Balance Sheet at June 30, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Fair Value Measurements [Abstract]
Estimated fair value of future contingent consideration	$1,063	$953
Accretion expense	$110

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation Of Contingent Consideration Liability) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Fair Value Measurements [Abstract]
Beginning balance - contingent consideration	$953
Accretion expense	110
Ending balance - contingent consideration	1,063
Contractual consideration	4,393
Total deferred acquisition liability	$5,456

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	9 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved	2,372,309
Shares available for future grants	1,326,703
Options expiration period, years	10 years
Vesting percentage after first year of service	25.00%
Share-based compensation, percentage of options vesting each month after year one	2.78%
1991 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares expired and forfeited	772,309
Non-Vested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	46,000
Weighted-average period for recognition of compensation cost, in years	1 year 7 months 6 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	37,000
Weighted-average period for recognition of compensation cost, in years	2 years 4 months 24 days
Performance Shares For Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	10,000

StockBased_Compensation_Amount

Stock-Based Compensation (Amounts Recognized In Financial Statements Related To Stock-Based Compensation) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$16	$47	$53	$169
Cost Of Goods Sold [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	1	2	2	7
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	6	12	15	40
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	8	27	33	102
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$1	$6	$3	$20

StockBased_Compensation_Assump

Stock-Based Compensation (Assumptions Used To Estimate Fair Value Of Options Granted) (Details)	9 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]
Volatility	83.66%
Risk-free interest rate	0.67%
Expected option life	3 years 1 month 6 days
Stock dividend yield

StockBased_Compensation_Summar

Stock-Based Compensation (Summary Of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Mar. 31, 2015
Stock-Based Compensation [Abstract]
Outstanding at July 1, 2014, Number of Options	1,704,042
Options forfeited, Number of Options	-31,044
Options expired, Number of Options	-503,125
Outstanding at March 31, 2015, Number of Options	1,169,873
Exercisable at March 31, 2015, Number of Options	1,024,729
Outstanding at July 1, 2014, Weighted-avg. Exercise Price Per Option	$1.35
Options forfeited, Weighted-avg. Exercise Price Per Option	$0.52
Options expired, Weighted-avg. Exercise Price Per Option	$1.79
Outstanding at March 31, 2015, Weighted-avg. Exercise Price Per Option	$1.18
Exercisable at March 31, 2015, Weighted-avg. Exercise Price Per Option	$1.26
Outstanding at March 31, 2015, Weighted-avg. Remaining Contractual Term	5 years 1 month 21 days
Exercisable at March 31, 2015, Weighted-avg. Remaining Contractual Term	4 years 9 months 4 days
Outstanding at July 1, 2014, Aggregate Intrinsic Value
Outstanding at March 31, 2015, Aggregate Intrinsic Value
Exercisable at March 31, 2015, Aggregate Intrinsic Value

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary Of Non-Vested Restricted Stock Activity) (Details) (Restricted Stock [Member], USD $)	9 Months Ended
	Mar. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at June 30, 2014, Number of Restricted Stock Awards	346,302
Awards granted, Number of Restricted Stock Awards	571,820
Awards forfeited, Number of Restricted Stock Awards	-55,000
Awards vested, Number of Restricted Stock Awards	-327,500
Non-vested at March 31, 2015, Number of Restricted Stock Awards	535,622
Non-vested at June 30, 2014, Weighted-avg. Grant-Date Fair Value	$0.28
Awards granted, Weighted-avg. Grant-Date Fair Value	$0.11
Awards forfeited, Weighted-avg. Grant-Date Fair Value	$0.18
Awards vested, Weighted-avg. Grant-Date Fair Value	$0.27
Non-vested at March 31, 2015, Weighted-avg. Grant-Date Fair Value	$0.11

Basic_And_Diluted_Loss_Per_Sha1

Basic And Diluted Loss Per Share (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding, basic and dilutive	21,838,000	21,326,000	21,701,000	21,195,000
Exercise Price Above Average Market Price [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive stock options excluded from diluted weighted average common shares outstanding	1,180,000	1,790,000	1,430,000	1,810,000
Exercise Price Below Average Market Price [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive stock options excluded from diluted weighted average common shares outstanding	0	0	0	0

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization, including amortization recorded in cost of goods sold, of intangible assets	$49,000	$61,000	$154,000	$172,000
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets					274,000
Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets					95,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets					$65,000
Prostiva Acquisition [Member] | Patents And Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, amortization period, in years			9 years
Prostiva Acquisition [Member] | Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, amortization period, in years			9 years
Prostiva Acquisition [Member] | Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, amortization period, in years			16 years

Intangible_Assets_Schedule_Of_

Intangible Assets (Schedule Of Intangible Assets) (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Carrying Value	$4,773	$4,759
Accumulated Amortization	-3,109	-2,955
Impairment	-434	-434
Net Carrying Value	1,230	1,370
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	88	74
Accumulated Amortization	-15	-11
Net Carrying Value	73	63
Prostiva Acquisition [Member] | Patents And Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	1,529	1,529
Accumulated Amortization	-542	-443
Impairment	-274	-274
Net Carrying Value	713	812
Prostiva Acquisition [Member] | Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	531	531
Accumulated Amortization	-188	-154
Impairment	-95	-95
Net Carrying Value	248	282
Prostiva Acquisition [Member] | Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	325	325
Accumulated Amortization	-64	-53
Impairment	-65	-65
Net Carrying Value	196	207
EDAP Acquisition [Member] | Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Value	2,300	2,300
Accumulated Amortization	-2,300	-2,294
Net Carrying Value		$6

Intangible_Assets_Future_Amort

Intangible Assets (Future Amortization Expense Related To Net Carrying Amount Of Intangible Assets) (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Intangible Assets [Abstract]
2015	$50
2016	199
2017	199
2018	198
2019	$196

Inventories_Narrative_Details

Inventories (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Inventory write-down	$739,000
Long-term inventories		94,000	141,000
Provista Acquisition [Member]
Business Acquisition [Line Items]
Inventory write-down	$504,000

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Inventories [Abstract]
Raw materials	$641	$685
Work-in-process	157	127
Finished goods	615	726
Total inventories	$1,413	$1,538

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	Jun. 30, 2014
Income Taxes [Abstract]
Gross unrecognized tax benefits	$14,000

Warranty_Details

Warranty (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Warranty [Abstract]
Maximum number of months covered by warranties	24 months
Beginning Balance	$56	$58
Warranty Provisions	6	35
Warranty Claims	-25	-30
Ending Balance	$37	$63

Financing_Arrangements_Details

Financing Arrangements (Details) (USD $)	9 Months Ended
	Mar. 31, 2015
Financing Arrangements [Abstract]
Promissory note payable	$5,300,000
Promissory note, interest rate	6.00%
Promissory note payable date	31-Mar-19
Principal and interest payment due	$1,300,000

Subsequent_Event_Narrative_Det

Subsequent Event (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Apr. 14, 2015
Subsequent Event [Line Items]
Principal and interest payment due	$1.30
Amount due and unpaid	2.8
Subsequent Event [Member]
Subsequent Event [Line Items]
Amount due and unpaid		$7.40